相关实验视频

Updated: May 30, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

五名患有自身免疫性肺膜蛋白质症的患者的长期结局,这些患者接受了molgramostim吸入溶液的治疗

Celia Montaño¹, Elisabeth Bendstrup², Ida Rønnov-Jessen²

¹Interstitial Lung Diseases Unit, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), CIBERES, Barcelona, Spain.

ERJ open research

|January 28, 2025

概括

自身免疫性肺膜蛋白质症 (aPAP) 是一种罕见的肺部疾病. 吸入的molgramostim是一种颗粒细胞-巨细胞殖民地刺激因子 (GM-CSF),对aPAP患者显示有希望的长期益处.

科学领域:

肺部病理学肺部病理学
免疫学免疫学免疫学
罕见疾病罕见疾病

背景情况:

自身免疫性肺膜蛋白质症 (aPAP) 是一种罕见的肺部疾病,由阻断GM-CSF信号的GM-CSF自身抗体引起.
这种阻塞会损害表面活性剂的清除,导致气膜表面活性剂的积累和减少气体交换.
目前的治疗,全肺洗 (WLL),是侵入性的,并没有解决根本原因.

研究的目的:

在患有自身免疫性肺膜蛋白质症 (aPAP) 的患者中研究吸入molgramostim的长期疗效.
探索aPAP的替代治疗方法,解决潜在的病理生理学问题.

主要方法:

一个真实的案例系列,涉及五名aPAP患者.
进行的治疗是吸入的molgramostim溶液,这是一种正在研究中的重组GM-CSF.
专注于具有具有挑战性的治疗历史的患者.

主要成果:

该研究观察到吸入molgramostim在接受治疗的aPAP患者中具有有益的长期影响.
吸入molgramostim在治疗这种罕见的肺病方面表现出积极的结果.

结论:

吸入的molgramostim可能为自身免疫性肺膜蛋白质症 (aPAP) 提供一个可行的治疗选择.
这种方法准了潜在的疾病机制,为像WLL这样的侵入性治疗提供了潜在的替代方案.

更多相关视频

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

相关概念视频

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...